The display and use of drug information on this site is subject to express terms of use. By continuing to view the drug information, you agree to abide by such terms ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
The goals of treatment are to decrease the frequency of angina, increase longevity, and improve patients' QOL. Management of risk factors is an essential component of this therapy. Also important is ...
LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global angina pectoris drugs market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021.
While grocery store shelves may be empty, firewood piles filled and cell phones charged, there may be a few more items to check off on your prep list for the upcoming winter storms. Along with the ...
PCI for coronary chronic total occlusion significantly improves angina symptom scores compared with placebo in patients with stable angina.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results